News Conference News HFSA 2025 CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF Yael L. Maxwell September 29, 2025
News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News ESC 2024 ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions Michael O'Riordan September 17, 2024
News Conference News NY Valves 2024 Polymer Mitral Valve Shows Well Early, but Long-term Data Key Michael O'Riordan June 12, 2024
News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News TCT 2023 SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC Yael L. Maxwell October 30, 2023
News Conference News ESC Heart Failure 2023 More ARNI Insights Fortify Role in ‘Below Normal’ LVEF: PARAGLIDE-HF Shelley Wood May 22, 2023
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News PCR London Valves 2021 Good Results but Small Numbers With JenaValve Trilogy in Severe AR Michael O'Riordan November 26, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020